Depression and senile dementia of the Alzheimer type: a role for moclobemide

@article{ChanPalay2005DepressionAS,
  title={Depression and senile dementia of the Alzheimer type: a role for moclobemide},
  author={Victoria Chan‐Palay},
  journal={Psychopharmacology},
  year={2005},
  volume={106},
  pages={S137-S139}
}
Depression is common in patients with senile dementia of the Alzheimer type (SDAT) and may precede the onset of the dementia; the underlying biological and neurotransmitter mechanisms may be common to both diseases, so far as norepinephrine lesions are concerned. The major routes of metabolism of amines in the brain utilize the monoamine oxidase (MAO) enzymes. Due to the consistent severity of norepinephrine lesions in the locus coeruleus of patients with pre-senile dementia or SDAT and the… Expand
Noradrenergic mechanisms in neurodegenerative diseases: a theory
TLDR
Evidence is given here to evidence that several neurodegenerative diseases and syndromes share common elements, including profound LC cell loss, and may in fact be different manifestations of a common pathophysiological process. Expand
Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases
  • M. Youdim
  • Chemistry, Medicine
  • Journal of Neural Transmission
  • 2018
TLDR
Recent novel therapeutic drugs for neurodegenerative diseases has led to the development of multi target drugs, that possess selective brain MAO A and B inhibitory moiety, iron chelating and antioxidant activities and the ability to increase brain levels of endogenous neurotrophins. Expand
MAO-inhibitors in Parkinson's Disease
TLDR
In general, the clinical use of MAO-I nowadays is underestimated and there should be more efforts to evaluate their clinical potency as antidepressants and antidementive drugs in addition to the final proof of their disease-modifying potential. Expand
Monoamine oxidase-A physically interacts with presenilin-1(M146V) in the mouse cortex.
TLDR
A physical interaction between PS-1 and MAO-A that could influence MAo-A activity and contribute to the monoaminergic disruptions common to disorders as seemingly diverse as depression and AD is supported. Expand
Alzheimer disease-related presenilin-1 variants exert distinct effects on monoamine oxidase-A activity in vitro
TLDR
A direct influence of PS-1 variants on MAO-A function could provide an explanation for the changes in monoaminergic tone observed in several neurodegenerative processes including AD. Expand
Moclobemide: therapeutic use and clinical studies.
  • U. Bonnet
  • Psychology, Medicine
  • CNS drug reviews
  • 2003
Moclobemide is a reversible inhibitor of monoamine-oxidase-A (RIMA) and has been extensively evaluated in the treatment of a wide spectrum of depressive disorders and less extensively studied inExpand
Flavoproteínas que actúan como amino-oxidasas: Estructura, función e importancia clínica
TLDR
Las poliaminas y las enzimas de su metabolismo desempenan funciones relevantes en los procesos de envejecimiento y en algunas enfermedades, como cancer, diabetes mellitus, accidentes cerebro-vasculares, insuficiencia renal y trastornos psiquiatricos. Expand

References

SHOWING 1-10 OF 25 REFERENCES
Depression and Senile Dementia of the Alzheimer Type: Catecholamine Changes in the Locus coeruleus – Basis for Therapy
This paper describes the clinical, psychometric, neuropathological, and neurotransmitter studies on 8 patients selected from the ZUrich study on dementia. It confirms the age-related loss ofExpand
Alzheimer's disease and senile dementia: Biochemical characteristics and aspects of treatment
TLDR
The well-known Alzheimer lesions in the brains of patients with AD and SD are described, as is the loss of neurons in the locus coeruleus, and biochemical changes can be given pathogenetic importance. Expand
Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression
TLDR
Qualitative and quantitative investigations of the norepinephrine neurons in the locus coeruleus in the LC in two neurodegenerative disorders, the senile dementia of the Alzheimer type and Parkinson's disease, are provided. Expand
Overlapping symptoms of geriatric depression and Alzheimer-type dementia.
TLDR
In this review of the course, symptomatology, and pathophysiology of Alzheimer-type dementia and geriatric depression, the authors describe the symptoms often shared by these diseases as well as the characteristics usually associated with one or the other. Expand
Monoamine Oxidase and Dementia: Treatment with an Inhibitor of MAO-B Activity
Patients suffering from Alzheimer type dementia have demonstrated an increase in MAO-B activity. Treatment of these patients with an inhibitor of the monoamine oxidase activity, such as L-DeprenylExpand
Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease
TLDR
Dose-dependent reductions in monoamine metabolites are consistent with in vitro biochemical and anatomical data from primate brain suggesting that at low doses of deprenyl, MAO-B inhibition might be expected to selectively affect dopamine and serotonin-containing neurons, while at higher doses, noradrenergic neurons may become relatively more affected by the drug. Expand
Monoamine Oxidase Inhibitors in Parkinson’s Disease
Following the seminal discovery by Ehringer and Hornykiewicz (1960) of the nigrostriatal dopamine deficiency of Parkinson’s disease, one obvious therapeutic strategy was to inhibit monoamine oxidaseExpand
THE INVESTIGATION OF DEMENTIA: RESULTS IN 200 CONSECUTIVE ADMISSIONS
TLDR
It is recommended that all patients with a provisional diagnosis of dementia be investigated early in the course of their illnesses in anticipation of the finding of a reversible dementia or a treatable pseudodementing illness. Expand
Depression and dementia in Parkinson's disease. Catecholamine changes in the locus ceruleus, a basis for therapy.
TLDR
Clinical, psychometric, neuropathological, and neurotransmitter immunocytochemical studies on 9 patients selected from the Zurich study on dementia and Parkinson''s disease are described. Expand
Monoamine oxidase inhibitors in Parkinson’s disease
As mentioned before, PD is the second most common neurodegenerative disease, with incidence sharply increasing with age (Prediger et al., 2012). The motor symptoms associated with PD are consideredExpand
...
1
2
3
...